Robert Haddad (@drhaddadrobert) 's Twitter Profile
Robert Haddad

@drhaddadrobert

Division Chief, Head and Neck Oncology.
Dana Farber Cancer Institute.
McGraw Chair in Head and Neck Oncology
Professor of Medicine. Harvard Medical School

ID: 81911264

calendar_today12-10-2009 19:45:37

199 Tweet

1,1K Followers

211 Following

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ Results from #COSMIC-313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…

1/ Results from #COSMIC-313 are out  <a href="/NEJM/">NEJM</a>: 1st  triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by <a href="/CharlesSwanton/">Charles Swanton</a> <a href="/AndresC27622123/">Andres Cervantes</a> #ESMO22

Thread 🧵==&gt; 

nejm.org/doi/full/10.10…
Memorial Sloan Kettering Radiation Oncology (@msk_radonc) 's Twitter Profile Photo

This review discusses cisplatin ineligibility in pts with locally advanced #HNC #hncsm, summarizes the limited clinical evidence for adjuvant tx, & highlights ongoing clinical trials that have the potential to provide new tx options. sciencedirect.com/science/articl…

This review discusses cisplatin ineligibility in pts with locally advanced #HNC #hncsm, summarizes the limited clinical evidence for adjuvant tx, &amp; highlights ongoing clinical trials that have the potential to provide new tx options.
sciencedirect.com/science/articl…
AACR (@aacr) 's Twitter Profile Photo

.Sue Yom, Robert Haddad, Nicole C. Schmitt, Angela L. Ferguson, and Barbara A. Burtness discussed "Clinical Trials" in a plenary session today at the AACR-AHNS Head and Neck Cancer Conference. #aacrAHNS23

.<a href="/sueyom/">Sue Yom</a>, <a href="/DrHaddadRobert/">Robert Haddad</a>, Nicole C. Schmitt, Angela L. Ferguson, and Barbara A. Burtness discussed "Clinical Trials" in a plenary session today at the AACR-AHNS Head and Neck Cancer Conference.
#aacrAHNS23
Dana-Farber News (@danafarbernews) 's Twitter Profile Photo

First targeted therapy found safe and shows anti-tumor activity in patients with rare head and neck cancer. Dana-Farber's Robert Haddad, MD (Robert Haddad) details the findings that were presented at #ESMO23.

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

I’m teaming up with Robert Haddad to play pickeball against Rob Gronkowski and raise funds for cancer research for Dana-Farber ! Help us beat the Gronk (and Cancer!) charity.pledgeit.org/f/ozX6IMVf7v

I’m teaming up with <a href="/DrHaddadRobert/">Robert Haddad</a> to play pickeball against <a href="/RobGronkowski/">Rob Gronkowski</a> and raise funds for cancer research for <a href="/DanaFarber/">Dana-Farber</a> !

Help us beat the Gronk (and Cancer!)

charity.pledgeit.org/f/ozX6IMVf7v
OncoDaily (@oncodaily) 's Twitter Profile Photo

Did you know Robert Haddad and Toni Choueiri, MD had a competitive streak? - Dana-Farber Rob Gronkowski #Cancer #CancerResearch #DanaFarberCancerInstitute #YouthFoundation #Clinic #NationalCancerInstitute #OncoDaily #Oncology oncodaily.com/49490.html

The Jimmy Fund (@thejimmyfund) 's Twitter Profile Photo

Doug is celebrating six years cancer-free this month! “When you have cancer, you say yes to things. You live life," he says. Your donation will help more patients like Doug become cancer-free. Let’s strike out cancer: jimmyfund.gives/KCANCER #KCANCER

Doug is celebrating six years cancer-free this month!

“When you have cancer, you say yes to things. You live life," he says.

Your donation will help more patients like Doug become cancer-free. Let’s strike out cancer: jimmyfund.gives/KCANCER

#KCANCER
OncLive.com (@onclive) 's Twitter Profile Photo

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024 @kevinhaigislab Mark Awad joaquim bellmunt Brad Bernstein Ed Chouchani Garrett Lab Robert Haddad Nancy Lin, MD @DrMatulonis @meyersonlab @danafarber #oncology onclive.com/view/dana-farb…

Dana-Farber News (@danafarbernews) 's Twitter Profile Photo

In the first advance in 20+ years for pts with locally advanced #HeadAndNeckCancer, a phase 3 clinical trial presented by Ravi Uppaluri, MDPhD at #AACR25 shows pembrolizumab before and after standard-of-care surgery significantly extends event-free survival. Robert Haddad Dana-Farber

In the first advance in 20+ years for pts with locally advanced #HeadAndNeckCancer, a phase 3 clinical trial presented by <a href="/DrUppaluri/">Ravi Uppaluri, MDPhD</a> at #AACR25 shows pembrolizumab before and after standard-of-care surgery significantly extends event-free survival. <a href="/DrHaddadRobert/">Robert Haddad</a> <a href="/DanaFarber/">Dana-Farber</a>
Dana-Farber News (@danafarbernews) 's Twitter Profile Photo

Head and neck cancer study shows immunotherapy improved outcomes in patients in curative setting. Dana-Farber Principal Investigator Robert Haddad discusses the Phase 3 KEYNOTE-689 study presented at #AACR25 by Ravi Uppaluri, MDPhD (Dana-Farber & Brigham and Women's Hospital)

Clinical Care Options (@cco_education) 's Twitter Profile Photo

Join us for an interactive symposium in conjunction with #AHNS2025 in which a panel of experts, Barbara Burtness, MD, Robert Haddad, MD, and Cristina Rodriguez, MD, will discuss the nuances of #immunotherapy and targeted therapy for patients with head and neck squamous cell

Join us for an interactive symposium in conjunction with #AHNS2025 in which a panel of experts, Barbara Burtness, MD, Robert Haddad, MD, and Cristina Rodriguez, MD, will discuss the nuances of #immunotherapy and targeted therapy for patients with head and neck squamous cell
Dana-Farber News (@danafarbernews) 's Twitter Profile Photo

Head and neck cancer research in NEJM – The addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improved event-free survival among patients with resectable locally advanced squamous-cell carcinoma. Research led by Dana-Farber Brigham Cancer Center's

Head and neck cancer research in <a href="/NEJM/">NEJM</a> – The addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improved event-free survival among patients with resectable locally advanced squamous-cell carcinoma. Research led by <a href="/DanaFarber/">Dana-Farber</a> Brigham Cancer Center's